{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T23:25:09Z","timestamp":1786922709741,"version":"build-2736575974"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,16]]},"DOI":"10.7759\/cureus.114617","type":"journal-article","created":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:48:43Z","timestamp":1786920523000},"source":"Crossref","is-referenced-by-count":0,"title":["Factors Associated With Discordance Between the Activated Partial Thromboplastin Time and Anti-factor Xa Activity During Extracorporeal Membrane Oxygenation: A Retrospective Cohort Study"],"prefix":"10.7759","author":[{"given":"Brian","family":"Simms","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Carmona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MOP.0000000000001247","article-title":"Anticoagulation and hemostasis on extracorporeal membrane oxygenation","volume":"35","author":"Carmona C","year":"2023","unstructured":"Carmona C, Nellis ME, Karam O. Anticoagulation and hemostasis on extracorporeal membrane oxygenation. Curr Opin Pediatr. 2023, 35:297-302. 10.1097\/MOP.0000000000001247","journal-title":"Curr Opin Pediatr"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2016.00067","article-title":"Anticoagulation management and monitoring during pediatric extracorporeal life support: a review of current issues","volume":"4","author":"Ryerson LM","year":"2016","unstructured":"Ryerson LM, Lequier LL. Anticoagulation management and monitoring during pediatric extracorporeal life support: a review of current issues. Front Pediatr. 2016, 4:67. 10.3389\/fped.2016.00067","journal-title":"Front Pediatr"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000001652","article-title":"2021 ELSO adult and pediatric anticoagulation guidelines","volume":"68","author":"McMichael AB","year":"2022","unstructured":"McMichael AB, Ryerson LM, Ratano D, Fan E, Faraoni D, Annich GM. 2021 ELSO adult and pediatric anticoagulation guidelines. ASAIO J. 2022, 68:303-10. 10.1097\/MAT.0000000000001652","journal-title":"ASAIO J"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/ehf2.14816","article-title":"Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support","volume":"11","author":"Li S","year":"2024","unstructured":"Li S, Li A, Beckman JA, et al.. Discordance between aPTT and anti-Xa in monitoring heparin anticoagulation in mechanical circulatory support. ESC Heart Fail. 2024, 11:2742-8. 10.1002\/ehf2.14816","journal-title":"ESC Heart Fail"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1309\/AJCPS6OW6DYNOGNH","article-title":"Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring: biochemical basis for discordance","volume":"139","author":"Takemoto CM","year":"2013","unstructured":"Takemoto CM, Streiff MB, Shermock KM, Kraus PS, Chen J, Jani J, Kickler T. Activated partial thromboplastin time and anti-Xa measurements in heparin monitoring: biochemical basis for discordance. Am J Clin Pathol. 2013, 139:450-6. 10.1309\/AJCPS6OW6DYNOGNH","journal-title":"Am J Clin Pathol"},{"key":"ref6","doi-asserted-by":"crossref","DOI":"10.1177\/02676591241309841","article-title":"Concordance and discordance of anticoagulation assays in children supported by ECMO: the truth is out there","volume":"40","author":"Carmona CA","year":"2025","unstructured":"Carmona CA, Bain J, Karam O. Concordance and discordance of anticoagulation assays in children supported by ECMO: the truth is out there. Perfusion. 2025, 40:1592-9.","journal-title":"Perfusion"},{"key":"ref7","doi-asserted-by":"crossref","DOI":"10.1177\/08850666241313357","article-title":"Anticoagulation monitoring strategies during extracorporeal membrane oxygenation (ECMO) therapy - differences between simultaneously obtained coagulation tests: a retrospective single-center cohort study","volume":"40","author":"Reisinger AC","year":"2025","unstructured":"Reisinger AC, Schneider N, Koellinger M, et al.. Anticoagulation monitoring strategies during extracorporeal membrane oxygenation (ECMO) therapy - differences between simultaneously obtained coagulation tests: a retrospective single-center cohort study. J Intensive Care Med. 2025, 40:651-9.","journal-title":"J Intensive Care Med"},{"key":"ref8","doi-asserted-by":"crossref","DOI":"10.1177\/02676591221151027","article-title":"Epidemiology of anticoagulation for children supported by extracorporeal membrane oxygenation in the United States: a Pediatric Hospital Information System database study","volume":"39","author":"Nellis ME","year":"2024","unstructured":"Nellis ME, An A, Mahmood H, Prishtina F, Hena Z, Karam O. Epidemiology of anticoagulation for children supported by extracorporeal membrane oxygenation in the United States: a Pediatric Hospital Information System database study. Perfusion. 2024, 39:536-42.","journal-title":"Perfusion"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.3389\/fped.2021.673613","article-title":"Epidemiology of the use of hemostatic agents in children supported by extracorporeal membrane oxygenation: a Pediatric Health Information System database study","volume":"9","author":"Nellis ME","year":"2021","unstructured":"Nellis ME, Vasovic LV, Goel R, Karam O. Epidemiology of the use of hemostatic agents in children supported by extracorporeal membrane oxygenation: a Pediatric Health Information System database study. Front Pediatr. 2021, 9:673613. 10.3389\/fped.2021.673613","journal-title":"Front Pediatr"},{"key":"ref10","doi-asserted-by":"crossref","DOI":"10.1177\/0267659120952982","article-title":"Anti-Xa versus time-guided anticoagulation strategies in extracorporeal membrane oxygenation: a systematic review and meta-analysis","volume":"36","author":"Willems A","year":"2021","unstructured":"Willems A, Roeleveld PP, Labarinas S, Cyrus JW, Muszynski JA, Nellis ME, Karam O. Anti-Xa versus time-guided anticoagulation strategies in extracorporeal membrane oxygenation: a systematic review and meta-analysis. Perfusion. 2021, 36:501-12.","journal-title":"Perfusion"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1097\/MAT.0000000000000986","article-title":"Correlation among antifactor Xa, activated partial thromboplastin time, and heparin dose and association with pediatric extracorporeal membrane oxygenation complications","volume":"66","author":"McMichael AB","year":"2020","unstructured":"McMichael AB, Hornik CP, Hupp SR, Gordon SE, Ozment CP. Correlation among antifactor Xa, activated partial thromboplastin time, and heparin dose and association with pediatric extracorporeal membrane oxygenation complications. ASAIO J. 2020, 66:307-13. 10.1097\/MAT.0000000000000986","journal-title":"ASAIO J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.thromres.2017.07.006","article-title":"Should we abandon the APTT for monitoring unfractionated heparin?","volume":"157","author":"Arachchillage DR","year":"2017","unstructured":"Arachchillage DR, Kamani F, Deplano S, Banya W, Laffan M. Should we abandon the APTT for monitoring unfractionated heparin?. Thromb Res. 2017, 157:157-61. 10.1016\/j.thromres.2017.07.006","journal-title":"Thromb Res"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1378\/chest.11-2291","article-title":"Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Garcia DA","year":"2012","unstructured":"Garcia DA, Baglin TP, Weitz JI, Samama MM. Parenteral anticoagulants: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012, 141:e24S-43S. 10.1378\/chest.11-2291","journal-title":"Chest"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra2104091","article-title":"Heparin resistance - clinical perspectives and management strategies","volume":"385","author":"Levy JH","year":"2021","unstructured":"Levy JH, Connors JM. Heparin resistance - clinical perspectives and management strategies. N Engl J Med. 2021, 385:826-32. 10.1056\/NEJMra2104091","journal-title":"N Engl J Med"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2022.02.052","article-title":"Anticoagulation for percutaneous ventricular assist device-supported cardiogenic shock: JACC review topic of the week","volume":"79","author":"Vandenbriele C","year":"2022","unstructured":"Vandenbriele C, Arachchillage DJ, Frederiks P, et al.. Anticoagulation for percutaneous ventricular assist device-supported cardiogenic shock: JACC review topic of the week. J Am Coll Cardiol. 2022, 79:1949-62. 10.1016\/j.jacc.2022.02.052","journal-title":"J Am Coll Cardiol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-023-00701-3","article-title":"Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: a retrospective observational study","volume":"11","author":"Saito T","year":"2023","unstructured":"Saito T, Hayakawa M, Kumano O, et al.. Variation in coagulation factor activity levels cause discrepancies between activated partial thromboplastin time and anti-Xa activity for heparin monitoring: a retrospective observational study. J Intensive Care. 2023, 11:54. 10.1186\/s40560-023-00701-3","journal-title":"J Intensive Care"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0000000000000028","article-title":"Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*","volume":"15","author":"Liveris A","year":"2014","unstructured":"Liveris A, Bello RA, Friedmann P, et al.. Anti-factor Xa assay is a superior correlate of heparin dose than activated partial thromboplastin time or activated clotting time in pediatric extracorporeal membrane oxygenation*. Pediatr Crit Care Med. 2014, 15:e72-9. 10.1097\/PCC.0000000000000028","journal-title":"Pediatr Crit Care Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/PCC.0b013e31825b582e","article-title":"Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation","volume":"13","author":"Maul TM","year":"2012","unstructured":"Maul TM, Wolff EL, Kuch BA, Rosendorff A, Morell VO, Wearden PD. Activated partial thromboplastin time is a better trending tool in pediatric extracorporeal membrane oxygenation. Pediatr Crit Care Med. 2012, 13:e363-71. 10.1097\/PCC.0b013e31825b582e","journal-title":"Pediatr Crit Care Med"},{"key":"ref19","doi-asserted-by":"crossref","DOI":"10.1345\/aph.1R635","article-title":"Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin","volume":"47","author":"Price EA","year":"2013","unstructured":"Price EA, Jin J, Nguyen HM, Krishnan G, Bowen R, Zehnder JL. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Ann Pharmacother. 2013, 47:151-8.","journal-title":"Ann Pharmacother"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/526289-factors-associated-with-discordance-between-the-activated-partial-thromboplastin-time-and-anti-factor-xa-activity-during-extracorporeal-membrane-oxygenation-a-retrospective-cohort-study","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,16]],"date-time":"2026-08-16T22:48:44Z","timestamp":1786920524000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/526289-factors-associated-with-discordance-between-the-activated-partial-thromboplastin-time-and-anti-factor-xa-activity-during-extracorporeal-membrane-oxygenation-a-retrospective-cohort-study"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,16]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.114617","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8,16]]}}}